Prostate cancer gene therapy and the role of radiation

Cancer Treatment Reviews

Volumn 28, Issue 1, 2002, Pages 49-64

  Kaminski, J M ^a   Nguyen, K ^a   Buyyounouski, M ^a   Pollack, A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Gene therapy; Prostate cancer; Radiation

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ADENOVIRUS VECTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOXYPEPTIDASE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOSINE DEAMINASE; CYTOTOXIN; FLUCYTOSINE; FLUOROURACIL; FLUTAMIDE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 2; LEUPRORELIN; LIPOSOME; N [4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYL]GLUTAMIC ACID; NITROREDUCTASE; ONCOLYTIC VIRUS; PHOSPHORIBOSYLTRANSFERASE; PLASMID DNA; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROTEIN P53; RETROVIRUS VECTOR; THYMIDINE KINASE; TIOGUANINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNINDEXED DRUG; VALACICLOVIR;

BYSTANDER EFFECT; CANCER CONTROL; CANCER LOCALIZATION; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; GENE REPLACEMENT THERAPY; GENE THERAPY; HERPES SIMPLEX VIRUS; HUMAN; IN VIVO STUDY; ISOTOPE LABELING; LIVER DYSFUNCTION; MALE; MEDICAL TECHNOLOGY; MOLECULAR BIOLOGY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; POXVIRUS; PROSTATE CANCER; REVIEW; URINARY TRACT DISEASE; VIRAL GENE DELIVERY SYSTEM;

EID: 0036086632     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1053/ctrv.2002.0250     Document Type: Article

References (236)

1. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years
2. T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years
3. Recombinant DNA and gene transfer website
4. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A
5. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer
6. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
7. Suicide gene therapy for prostate cancer using a replication-deficient adenovirus containing the herpesvirus thymidine kinase gene
8. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
9. Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer
10. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy
11. A phase I trial of cv706, a replication-competent, psa selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy
12. Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation
13. Prostate cancer radio-sensitization in vivo with adenovirus-mediated p53 gene therapy
14. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells
15. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation
16. Sustained enhancement of liposome-mediated gene delivery and gene expression in human breast tumour cells by ionizing radiation
17. CV706, a prostrate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity
18. The use of DNA viruses as vectors for gene therapy
19. The basic science of gene therapy
20. Gene therapy for prostate cancer. New perspectives on an old problem
21. Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen
22. Increased injection number enhances adenoviral genetic radiotherapy
23. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer
24. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis
25. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant, prostate tumor xenografts
26. Adenovirus and adeno-associated virus mediated gene transfer
27. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer
28. Infection of the adrenal gland as a route to the central nervous system after viraemia with herpes simplex virus in the mouse
29. Herpes simplex virus hepatitis in macrophage-depleted mice: The role of massive, apoptotic cell death in pathogenesis
30. Gene delivery and gene therapy with herpes simplex virus-based vectors
31. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma
32. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207
33. Vaccinia virus: A tool for research and vaccine development
34. In situ cytokine gene transfection using vaccinia virus vectors
35. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth
36. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases
37. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines
38. Folate receptor mediated DNA delivery into tumor cells: Potosomal disruption results in enhanced gene expression
39. Gene therapy of prostate cancer: P53, suicidal genes, and other targets
40. Stabilized plasmid-lipid particles: Construction and characterization
41. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice
42. Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene
43. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes
44. Increased expression of DNA cointroduced with nuclear protein in adult rat liver
45. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates
46. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma
47. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans
48. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis
49. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy
50. Drug sensitivity ('suicide') genes for selective cancer chemotherapy
51. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors
52. Prodrug-activated gene therapy: Involvement of an immunological component in the 'bystander effect'
53. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
54. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro
55. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins
56. The drug verapamil inhibits bystander killing but not cell suicide in thymidine kinase-ganciclovir prodrug-activated gene therapy
57. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro
58. Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase-mediated suicide gene therapy
59. Bystander effect caused by suicide gene expression indicates the feasibility of gene therapy for hepatocellular carcinoma
60. Preservation of the bystander cytocidal effect of irradiated herpes simplex virus thymidine kinase (HSV-tk) modified tumor cells
61. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system
62. Genetic delivery of enzymes for cancer therapy
63. Direct evidence for a bystander effect of ionizing radiation in primary human fibroblasts
64. Alpha particles initiate biological production of superoxide anions and hydrogen peroxide in human cells
65. Alpha particles induce the production of interleukin-8 by human cells
66. Intercellular communication is involved in the bystander regulation of gene expression in human cells exposed to very low fluences of alpha particles
67. A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow
68. Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models
69. Uptake of adenoviral vectors via fibroblast growth factor receptors involves intracellular pathways that differ from the targeting ligand
70. Functional and selective targeting of adenovirus to high-affinity Fcgamma receptor I-positive cells by using a bispecific hybrid adapter
71. Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin
72. Targeting of adenoviral vectors through a bispecific single-chain antibody
73. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105)
74. Highly efficient transduction of endothelial cells by targeted artificial virus-like particles
75. Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles
76. Tumor targeting using anti-her2 immunoliposomes
77. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies
78. Investigation of the cellular uptake of E-Selectin-targeted immunoliposomes by activated human endothelial cells
79. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer
80. STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors
81. Surface-epitope masking and expression cloning identifies the human prostate carcinoma tumor antigen gene PCTA-1 a member of the galectin gene family
82. Prostate-specific membrane antigen expression in normal and malignant human tissues
83. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: A study of 184 cases
84. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature
85. Heat-activated transgene expression from adenovirus vectors infected into human prostate cancer cells
86. Radiogenetic therapy: On the interaction of viral therapy and ionizing radiation for improving local control of tumors
87. The interaction between recombinant human tumor necrosis factor and radiation in 13 human tumor cell lines
88. Transgene expression in malignant glioma using a replication-defective adenoviral vector containing the Egr-1 promoter: Activation by ionizing radiation or uptake of radioactive iododeoxyuridine
89. Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer
90. The use of radiation-induced bacterial promoters in anaerobic conditions: A means to control gene expression in clostridium-mediated therapy for cancer
91. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters
92. Novel retroviral vector transferring a suicide gene and a selectable marker gene with enhanced gene expression by using a tetracycline-responsive expression system
93. Tetracycline-regulatable adenovirus vectors: Pharmacologic properties and clinical potential
94. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter
95. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element
96. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene
97. Prostate-specific antigen expression is regulated by an upstream enhancer
98. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter
99. Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene
100. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice
101. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer
102. Expression of the prostate-specific membrane antigen
103. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy
104. In vivo expression of prostate-specific adenoviral vectors in a canine model
105. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence
106. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer
107. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy
108. Technology evaluation: CN-706, Calydon Inc
109. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1
110. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
111. Tetracycline-induced expression of an anti-c-Myb single-chain antibody and its inhibitory effect on proliferation of the human leukemia cell line K562
112. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
113. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells
114. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation
115. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation
116. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer
117. Adenovirus-mediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo
118. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer
119. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers
120. Enhancement of radio-sensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene
121. Combined radiation and p53 gene therapy of malignant glioma cells
122. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: Changes in tumour cell proliferative activity
123. Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy
124. Diffusible cytotoxic metabolites contribute to the in vitro bystander effect associated with the cyclophosphamide/cytochrome P450 2B1 cancer gene therapy paradigm
125. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination
126. Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954
127. Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors
128. Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine
129. Suicide gene therapy on LNCaP human prostate cancer cells
130. Adenoviral-mediated transfer of a heat-inducible double suicide gene into prostate carcinoma cells
131. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity
132. Induction of potent antitumor natural killer cell activity by herpes simplex virus-thymidine kinase and ganciclovir therapy in an orthotopic mouse model of prostate cancer
133. Prospects for herpes-simplex-virus thymidine-kinase and cytokine gene transduction as immunomodulatory gene therapy for prostate cancer
134. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor transfer
135. The thymidine kinase/ganciclovir-mediated 'suicide' effect is variable in different tumor cells
136. Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: Implications for gene therapy
137. Differential chemosensitivity of breast cancer cells to ganciclovir treatment following adenovirus-mediated herpes simplex virus thymidine kinase gene transfer
138. Selective enhancement by an antiviral agent of the radiation-induced cell killing of human glioma cells transduced with HSV-tk gene
139. Retrovirus-mediated herpes simplex virus thymidine kinase gene transduction renders human thyroid carcinoma cell lines sensitive to ganciclovir and radiation in vitro and in vivo
140. Prodrug activation gene therapy and external beam irradiation in the treatment of prostate cancer
141. Regression of hepatocellular carcinoma in vitro and in vivo by radio-sensitizing suicide gene therapy under the inducible and spatial control of radiation
142. Enhanced therapeutic effect of HSV-tk+ GCV gene therapy and ionizing radiation for prostate cancer
143. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells
144. Combination suicide/cytokine gene therapy as adjuvants to a defective herpes simplex virus-based cancer vaccine
145. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminase gene
146. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts
147. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo
148. Selective augmentation of radiation effects by 5-fluorocytosine on murine B16(F10) melanoma cells transfected with cytosine deaminase gene
149. Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene
150. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation
151. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma
152. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: Comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase
153. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model
154. Cancer chemotherapy using suicide genes
155. The potential therapeutic gain of radiation-associated gene therapy with the suicide gene cytosine deaminase
156. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization
157. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy
158. A novel three-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene, and radiotherapy
159. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy
160. Demonstration of a rational strategy for human prostate cancer gene therapy
161. Prostate cancer gene therapy: Comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines
162. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis
163. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology
164. Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses
165. Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model
166. Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interleukin-12 gene therapy in a metastatic model of prostate cancer
167. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: Immunogene therapy using a highly secretable form of interleukin-15 gene transfer
168. Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta
169. Technology evaluation: TG-1031, Transgene SA
170. PSA-encoding adenovirus induces potent antitumor immunity in a mouse prostate tumor model
171. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy
172. Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft
173. A model using radiation and plasmid-mediated tumor necrosis factor-alpha gene therapy for treatment of glioblastomas
174. The treatment of malignant mesothelioma with a gene modified cancer cell line: A phase I study
175. Osteocalcin-directed gene therapy for prostate-cancer bone metastasis
176. Phase I/II trial evaluating combined radiotherapy and in situ gene therapy with or without hormonal therapy in the treatment of prostate cancer-A preliminary report
177. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells
178. Safety and feasibility of injection with an E1B-55kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial
179. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells
180. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy
181. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel
182. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse
183. Molecular and clinical activity of CN-706, a PSA-selective oncolytic Ad5 vector in a phase I trial in locally recurrent prostate cancer following radiation therapy
184. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus 1 vector G207
185. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates
186. The p53 tumour suppressor gene
187. P53 mutations in human cancers
188. Participation of p53 protein in the cellular response to DNA damage
189. p53 is required for radiation-induced apoptosis in mouse thymocytes
190. Relationship between radiation-induced G1 phase arrest and p53 function in human tumor cells
191. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer
192. P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy
193. P53 tumor suppressor gene therapy for cancer
194. Enhanced radiosensitivity of malignant glioma cells after adenoviral p53 transduction
195. Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells
196. Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer
197. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer
198. The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer
199. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers
200. Antitumor activity of bax and p53 naked gene transfer in lung cancer: In vitro and in vivo analysis
201. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene
202. A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax
203. Adenoviral Bak overexpression mediates caspase-dependent tumor killing
204. Adenovirus-mediated bax overexpression for the induction of therapeutic apoptosis in prostate cancer
205. Adenovirus-mediated E2F-1 gene transfer inhibits MDM2 expression and efficiently induces apoptosis in MDM2-overexpressing tumor cells
206. Adenovirus-mediated E2F-1 gene transfer efficiently induces apoptosis in melanoma cells
207. Gene transfer of FAS ligand induces tumor regression in vivo
208. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
209. Transduction and apoptosis induction in the rat prostate, using adenovirus vectors
210. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal anti-body-induced apoptopsis
211. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer
212. Adenovirus p16 gene therapy for prostate cancer
213. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde
214. Clinical phase I gene therapy trial using BRCA1 retrovirus is safe
215. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells
216. Suppression of prostate cancer invasive potential and matrix metalloproteinase activity by E-cadherin transfection
217. Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: Overexpression of caspase-7 as a new gene therapy strategy for prostate cancer
218. Cancer gene therapy using a pro-apoptotic gene, caspase-3
219. Adenovirus-mediated transfer of inducible caspases: A novel 'death switch' gene therapeutic approach to prostate cancer
220. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model
221. Inhibition of colonic tumor cell growth by biliary glycoprotein
222. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts
223. Adenovirus-mediated antisense ATM gene transfer sensitizes prostate cancer cells to radiation
224. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer
225. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides
226. Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides
227. DNA cleavage by 111In-labeled oligodeoxyribonucleotides
228. Sequence-specific DNA double-strand breaks induced by triplex forming 125I labeled oligonucleotides
229. Cloning and characterization of the thyroid iodide transporter
230. Iodide uptake and experimental 131I therapy in transplanted undifferentiated thyroid cancer cells expressing the Na+/I-symporter gene
231. Expression and activity of human Na+/I-symporter in human glioma cells by adenovirus-mediated gene delivery
232. Radioisotope concentrator gene therapy using the sodium/iodide symporter gene
233. In vivo sodium iodide symporter gene therapy of prostate cancer
234. Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy